CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-01 | Thomas John Director | Grant or award · Stock Option Right to Buy) | +50,469 | 50,469 | ||
| 2024-08-01 | Smither John W Director | Grant or award | +39,541 | 52,711 | ||
| 2024-08-01 | Smither John W Director | Grant or award · Stock Option Right to Buy) | +50,469 | 50,469 | ||
| 2024-06-24 | Yu Yong VP, Clinical Trial Operations | Sale | −6,849 | $2.12 | $15K | 10,869 |
| 2024-06-24 | Ryder Sean General Counsel | Sale | −5,496 | $2.12 | $12K | 19,388 |
| 2024-06-24 | Jewett Caroline Head of Quality | Sale | −4,961 | $2.12 | $11K | 16,174 |
| 2024-05-29 | Tyree James L Director | Purchase | +6,250 | 9,710 | ||
| 2024-05-29 | Tyree James L Director | Purchase · Common Stock Warrant (Right to Buy) | +6,250 | 6,250 | ||
| 2024-05-29 | Smither John W Director | Purchase | +6,250 | 13,170 | ||
| 2024-05-29 | Smither John W Director | Purchase · Common Stock Warrant (Right to Buy) | +6,250 | 6,250 | ||
| 2024-05-29 | Thomas John Director | Purchase | +2,500 | 465,960 | ||
| 2024-05-29 | Thomas John Director | Purchase · Common Stock Warrant (Right to Buy) | +2,500 | 2,500 | ||
| 2024-05-29 | Mirabelli Mary Director | Purchase | +8,000 | 12,460 | ||
| 2024-05-29 | Mirabelli Mary Director | Purchase · Common Stock Warrant (Right to Buy) | +8,000 | 8,000 | ||
| 2024-05-29 | Yu Yong VP, Clinical Trial Operations | Purchase | +2,500 | 2,500 | ||
| 2024-05-29 | Yu Yong VP, Clinical Trial Operations | Purchase · Common Stock Warrant (Right to Buy) | +2,500 | 2,500 | ||
| 2024-03-14 | Zindrick Thomas President and CEO | Grant or award | +26,264 | 50,207 | ||
| 2024-03-14 | Zak Lourie S. Chief Financial Officer | Grant or award | +3,852 | 38,428 | ||
| 2024-03-14 | Smalling Ralph Head of Regulatory | Grant or award | +2,107 | 18,144 | ||
| 2024-03-14 | Cappello Joseph VP, Pharmaceutical Development | Grant or award | +11,557 | 20,953 |
Page 8 of 9 · 170 trades